Zoetis
Trade Zoetis 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ZTS
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The firm operates through the United States and International geographical segments.
ZTS Key Statistics
Stock Snapshot
The current Zoetis(ZTS) stock price is $124.29, with a market capitalization of 54.77B. The stock trades at a price-to-earnings (P/E) ratio of 19.99 and offers a dividend yield of 1.7%.
As of 2025-12-16, Zoetis(ZTS) stock has fluctuated between $120.72 and $124.54. The current price stands at $124.29, placing the stock +3.0% above today's low and -0.2% off the high.
Zoetis(ZTS) shares are trading with a volume of 16.88M, against a daily average of 5.51M.
In the last year, Zoetis(ZTS) shares hit a 52-week high of $179.29 and a 52-week low of $115.25.
In the last year, Zoetis(ZTS) shares hit a 52-week high of $179.29 and a 52-week low of $115.25.
ZTS News
Zoetis (ZTS) stock rose over 2% on Monday after the animal health giant disclosed plans to raise $1.75 billion through a private offering of convertible senior...
BofA downgraded Zoetis (ZTS) to Neutral from Buy with a price target of $135, down from $165. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock...
Zoetis (ZTS) just packed a lot into a short stretch, from showcasing a fuller innovation pipeline to lifting its dividend and winning Canadian approval for a ne...
Analyst ratings
73%
of 22 ratingsMore ZTS News
Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...
Zoetis Inc. recently announced that Health Canada has approved Portela (relfovetmab injection), a monoclonal antibody designed to provide three months of osteoa...
HSBC lowered the firm’s price target on Zoetis (ZTS) to $140 from $180 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The...